IRIDEX (IRIX) Stock Price

Currency:

IRIDEX Price

🇺🇸NASDAQ·CLOSED

1.37USD

Market closed

Today +/-

+0.02 USD

Today %

+1.84 %

IRIDEX (IRIX) — ISIN US4626841013. The IRIDEX stock price was 1.37 USD in 2026. Revenue was 57.68 M USD. Earnings were -1.23 M USD. P/E ratio was -18.36. IRIDEX operates in the Health sector.

IRIDEX stock price

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of IRIDEX over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how IRIDEX stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing IRIDEX's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

IRIDEX Stock Price History

Date	IRIDEX Price
3/17/2026	1.37 USD
3/16/2026	1.35 USD
3/13/2026	1.30 USD
3/12/2026	1.34 USD
3/11/2026	1.36 USD
3/10/2026	1.37 USD
3/9/2026	1.32 USD
3/6/2026	1.21 USD
3/5/2026	1.39 USD
2/26/2026	1.48 USD
2/25/2026	1.54 USD
2/24/2026	1.47 USD
2/23/2026	1.44 USD
2/20/2026	1.41 USD
2/19/2026	1.42 USD
2/18/2026	1.41 USD
2/16/2026	1.32 USD

API Docs Get API Key

IRIDEX Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

Revenue

EBIT

Net Income

Details

API Docs Get API Key

IRIDEX Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 18, 2026, 4:11 AM

REVENUE (M USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (M USD)

NET INCOME (M USD)

NET INCOME GROWTH (%)

SHARES (M)

DOCUMENTS

1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e
2	4	5	7	8	12	18	23	26	32	27	30	31	32	37	35	55	48	31	32	33	33	38	42	41	46	41	42	43	36	53	56	51	48	53	57	61	64
–	100.00	25.00	40.00	14.29	50.00	50.00	27.78	13.04	23.08	-15.63	11.11	3.33	3.23	15.63	-5.41	57.14	-12.73	-35.42	3.23	3.13	–	15.15	10.53	-2.38	12.20	-10.87	2.44	2.38	-16.28	47.22	5.66	-8.93	-5.88	10.42	7.55	7.02	4.92
50.00	50.00	60.00	57.14	75.00	58.33	55.56	56.52	53.85	56.25	48.15	43.33	45.16	43.75	48.65	51.43	43.64	39.58	48.39	50.00	48.48	48.48	47.37	50.00	46.34	43.48	36.59	40.48	39.53	41.67	41.51	44.64	41.18	39.58	35.85	33.33	31.15	29.69
1	2	3	4	6	7	10	13	14	18	13	13	14	14	18	18	24	19	15	16	16	16	18	21	19	20	15	17	17	15	22	25	21	19	19	19	19	19
-1	0	0	1	1	1	2	1	1	2	-1	0	0	0	1	-5	-22	-7	2	3	2	1	2	10	0	-11	-12	-12	-8	-6	-5	-7	-9	-8	-4	-1	0	1
–	–	–	–	–	–	100.00	-50.00	–	100.00	-150.00	–	–	–	–	-600.00	340.00	-68.18	-128.57	50.00	-33.33	-50.00	100.00	400.00	–	–	9.09	–	-33.33	-25.00	-16.67	40.00	28.57	-11.11	-50.00	-75.00	–	–
1.37	1.37	4.25	4.24	4.35	6.41	6.76	6.77	6.85	7.29	6.76	6.93	7.07	7.2	7.88	7.71	8.29	8.82	9.94	10.13	10.23	8.94	10.1	10.36	10.13	10.17	11.56	12.2	13.71	13.84	15.42	15.94	16.13	16.44	16.44	16.44	16.44	16.44
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales IRIDEX generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IRIDEX retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IRIDEX's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares IRIDEX has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IRIDEX's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ASSETS

CASH BALANCE (M USD)

RECEIVABLES (M USD)

OTHER RECEIVABLES (M USD)OTHER REC. (M USD)

INVENTORIES (M USD)

OTHER CURRENT ASSETS (M USD)OTHER CURRENT LIAB. (M USD)

CURRENT ASSETS (M USD)

TANGIBLE ASSETS (M USD)

LONG-TERM INVESTMENTS (M USD)LONG-T. INVEST. (M USD)

LONG-TERM RECEIVABLES (M USD)LONG-T. REC. (M USD)

INTANGIBLE ASSETS (M USD)INTANGIBLE ASSETS (M USD)

GOODWILL (M USD)

OTHER NON-CURRENT ASSETS (M USD)OTHER NON-CURRENT ASSETS (M USD)

NON-CURRENT ASSETS (M USD)

TOTAL ASSETS (M USD)

LIABILITIES

COMMON STOCK (k USD)

ADDITIONAL PAID-IN CAPITAL (M USD)

RETAINED EARNINGS (M USD)

OTHER EQUITY (k USD)OTHER EQUITY (k USD)

UNREALIZED GAINS/LOSSES (M USD)UNREAL. GAINS/LOSSES (M USD)

EQUITY (M USD)

LIABILITIES (M USD)

PROVISIONS (M USD)

OTHER SHORT-TERM LIABILITIES (M USD)OTHER SHORT-TERM LIAB. (M USD)

SHORT-TERM DEBTS (M USD)SHORT-TERM DEBTS (M USD)

SHORT-TERM PORTION OF LONG-TERM DEBTS (M USD)LONG-TERM DEBT PORTION (M USD)

SHORT-TERM RECEIVABLES (M USD)SHORT-TERM REC. (M USD)

LONG-TERM LIABILITIES (M USD)LONG-T. LIAB. (M USD)

DEFERRED TAXES (M USD)

OTHER LIABILITIES (M USD)OTHER LIAB. (M USD)

LONG-TERM LIABILITIES (M USD)LONG-T. LIABILITIES (M USD)

DEBT (M USD)

TOTAL CAPITAL (M USD)

1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2022	2023	2024

0.68	1.23	15.11	13.49	10.88	13.15	12.99	9.1	11.54	16.29	13.7	21.43	21.05	5.81	5.31	9.38	8.35	10.79	11.9	13.44	13.3	10	23.75	21.71	21.19	12.65	11.63	23.85	23.85	13.92	7.03	2.39
1.92	2.48	5.39	6.06	7.61	8.26	8.01	8.07	8.04	6.55	7.4	6.59	6.05	8.88	8.2	7.48	5.46	5.55	5.48	7.35	8.34	9.28	10.03	7.86	9.08	9.32	7.29	6.61	6.61	6.23	6.73	5.95
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.11	3.11	3.54	2.93	2.44
0.64	1.26	1.86	3.98	6.5	7.26	9.72	12.56	10.73	8.72	8.92	8.59	9.5	15.97	11.64	9	5.63	6.66	8.04	10.61	9.12	11.11	11.64	9.38	8.79	8.17	5.71	7.61	7.61	10.61	9.91	10.82
0.7	1.09	0.64	1	0.96	0.44	0.81	0.6	1.84	1.9	2.62	2.31	1.26	4.85	0.54	0.47	6.94	6.5	1.64	0.58	2.14	0.39	0.45	0.5	0.55	0.4	0.73	1.07	1.07	1.47	0.86	1.96
3.94	6.06	23	24.53	25.95	29.11	31.53	30.33	32.15	33.46	32.64	38.92	37.86	35.51	25.69	26.33	26.38	29.5	27.06	31.98	32.9	30.78	45.87	39.45	39.61	30.54	25.36	42.25	42.25	35.77	27.45	23.56
0.08	0.25	0.66	2.13	2.27	2.14	1.9	1.54	0.95	0.85	0.85	1.11	1.09	1.62	0.83	0.49	0.34	0.33	0.48	0.54	0.74	1.1	1.53	1.4	1.22	3.49	1.88	2.99	2.99	2.13	2.98	1.91
0	0	0	0	0	0	0	0	0	0	4.32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0.1	0	0	0	0	0	0	0	0	5.94	1.47	1.15	0.82	0.75	0.55	0.33	0.28	0.27	0.13	0.12	0.1	0.08	0.07	2.21	2.21	1.98	1.64	1.31
0	0	0	0	0	0	0	0	0	0	0	0	0	3.24	0	0	0.47	0.53	0.53	0.53	0.53	0.53	0.53	0.53	0.53	0.53	0.53	0.97	0.97	0.97	0.97	0.97
0.4	0.1	0.05	0.03	0.07	1.52	1.59	1.92	1.18	1.52	1.27	1.07	1.22	0.35	0.23	0.32	1.22	1.04	0.29	0.3	7.37	9.15	0.08	0.14	0.2	0.15	0.13	0.27	0.27	1.46	1.4	1.39
0.48	0.35	0.71	2.16	2.44	3.66	3.49	3.46	2.13	2.37	6.44	2.18	2.31	11.15	2.53	1.96	2.85	2.65	1.85	1.7	8.92	11.05	2.27	2.19	2.05	4.25	2.61	6.44	6.43	6.54	6.99	5.57
4.42	6.41	23.71	26.69	28.39	32.77	35.02	33.79	34.28	35.83	39.08	41.1	40.17	46.66	28.22	28.29	29.23	32.15	28.91	33.68	41.82	41.83	48.14	41.64	41.66	34.79	27.97	48.69	48.69	42.31	34.44	29.13

30	40	60	70	70	70	70	70	70	70	70	80	80	100	100	100	100	100	100	100	110	110	120	130	150	150	150	170	168	170	172	174
5.24	5.49	21.25	21.55	21.8	22.12	22.69	23.42	23.63	23.9	25.28	26.33	29.7	38.7	39.11	39.82	41.17	42.03	38.96	40.67	38.51	37.99	55.16	59.39	71.55	73.09	74.18	85.26	85.26	86.8	88.44	89.88
-1.84	-0.84	0.17	2.27	4.01	5.32	8.05	6.77	6.92	7.3	6.89	8.56	2.81	-19.46	-26.83	-24.25	-21.2	-18.59	-17.15	-14.92	-4.88	-4.41	-16.12	-28.99	-41.8	-50.62	-56.94	-62.17	-62.17	-69.72	-79.04	-88.01
0	0	0	0	10	0	10	0	0	0	-40	-30	0	-90	-190	-210	-210	-40	0	0	0	0	0	0	70	80	-20	50	45	-20	-52	51
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.43	4.69	21.48	23.89	25.89	27.51	30.82	30.26	30.62	31.27	32.2	34.94	32.59	19.25	12.19	15.46	19.86	23.5	21.91	25.85	33.74	33.69	39.16	30.53	29.97	22.7	17.37	23.31	23.3	17.23	9.52	2.1
0.14	0.29	0.54	0.75	0.88	1.13	1.41	1.18	0.66	1.03	1.23	1.09	1.83	2.89	2.42	1.87	1.51	1.58	2.11	2.28	1.76	2.22	1.99	1.72	2.52	2.59	1.15	2.77	2.77	3.86	4.5	6.99
0.66	1.12	1.18	1.48	1.6	2.51	2.57	2.45	2.6	2.65	4.38	3.87	4.78	11.53	5.16	5.32	3	3.33	3.1	3.95	3.6	3.51	4.52	5.56	5.46	4.87	4.46	4.53	4.53	5.03	4.67	3.39
0	0.28	0.51	0.57	0.01	1.62	0.55	0.33	0.82	1.33	1.69	1.62	1.42	3.55	2.91	2.41	4.69	4	1.16	1.13	1.68	1.7	1.95	3.11	2.53	2.31	1.83	5.35	5.35	3.57	3.81	4.45
0.18	0	0	0	0	0	0	0	0	0	0	0	0	9.88	6	3.52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.01	0.01	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.25	0	0	0	0	1.73
0.98	1.7	2.24	2.8	2.49	5.26	4.53	3.96	4.08	5.01	7.3	6.58	8.03	27.85	16.49	13.12	9.2	8.91	6.37	7.36	7.04	7.43	8.46	10.39	10.51	9.77	8.69	12.65	12.65	12.46	12.97	16.56
0.02	0.01	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.25	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.15	0.6	0.81	0.64	0.46	1.04	0.7	0.52	0.73	1.21	2.33	0.67	12.74	12.74	12.61	11.94	9.48
0.02	0.01	0	0	0	0	0	0	0	0	0	0	0	0	0	0.15	0.6	0.81	0.64	0.46	1.04	0.7	0.52	0.73	1.21	2.33	1.92	12.74	12.74	12.61	11.94	10.48
1	1.71	2.24	2.8	2.49	5.26	4.53	3.96	4.08	5.01	7.3	6.58	8.03	27.85	16.49	13.27	9.8	9.72	7.01	7.82	8.08	8.13	8.98	11.12	11.72	12.1	10.61	25.39	25.39	25.07	24.91	27.04
4.43	6.4	23.72	26.69	28.38	32.77	35.35	34.22	34.7	36.28	39.5	41.52	40.62	47.1	28.68	28.73	29.66	33.22	28.92	33.67	41.82	41.82	48.14	41.65	41.69	34.8	27.98	48.7	48.69	42.3	34.44	29.14

Details

Balance Sheet

ⓘ

What Is the Balance Sheet?

The balance sheet is a financial snapshot of IRIDEX at a specific point in time. It follows the fundamental equation: Assets = Liabilities + Shareholders' Equity. Unlike the income statement (which covers a period), the balance sheet tells you what the company owns, what it owes, and what belongs to shareholders at a given date.

Assets

Current assets (cash, receivables, inventory) can be converted to cash within 12 months and indicate short-term liquidity. Non-current assets (property, equipment, intangible assets, goodwill) represent long-term investments. A high proportion of cash and short-term investments gives IRIDEX financial flexibility to weather downturns, fund acquisitions, or return capital to shareholders.

Liabilities

Current liabilities (accounts payable, short-term debt) are obligations due within one year. Non-current liabilities (long-term debt, pension obligations) are due further out. Key ratio to watch: the debt-to-equity ratio (Total Debt ÷ Shareholders' Equity). A ratio below 1.0 is generally healthy, meaning the company is funded more by equity than debt. Highly leveraged companies amplify both gains and losses.

Shareholders' Equity

Equity is the residual value belonging to shareholders after all debts are paid. It includes retained earnings (accumulated profits not paid out as dividends) and paid-in capital. Rising equity year over year is a positive sign — it means IRIDEX is building book value. Declining equity, especially when driven by losses or heavy share buybacks funded by debt, warrants closer scrutiny.

Key Ratios to Derive

From the balance sheet, you can calculate the current ratio (current assets ÷ current liabilities; above 1.5 is comfortable), book value per share (equity ÷ shares outstanding), and return on equity (net income ÷ equity; above 15 % is strong). Tracking these ratios over time reveals whether IRIDEX is strengthening or weakening its financial position.

NET INCOME (M USD)

DEPRECIATION AND AMORTIZATION M USDDEPRECIATION (M USD)

DEFERRED TAXES (M USD)

CHANGES IN WORKING CAPITAL (M USD)CHANGES IN WORKING CAPITAL (M USD)

NON-CASH ITEM (M USD)

PAID INTEREST (M USD)

PAID TAXES (M USD)

Net Cash Flow from Operating Activities (M USD)NET CASH FLOW FROM OPERATING ACTIVITIES (M USD)

CAPITAL EXPENDITURES (M USD)

CASH FLOW FROM INVESTING ACTIVITIES (M USD)CASH FLOW FROM INVESTING ACTIVITIES (M USD)

CASH FLOW FROM OTHER INVESTING ACTIVITIES (M USD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M USD)

INTEREST INCOME AND EXPENSES (M USD)

NET DEBT CHANGE (M USD)NET DEBT CHANGE (M USD)

Net change in equity (M USD)NET CHANGE IN EQUITY (M USD)

CASH FLOW FROM FINANCING ACTIVITIES (M USD)CASH FLOW FROM FINANCING ACTIVITIES (M USD)

OTHER ITEMS OF FINANCING CASH FLOWS (M USD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M USD)

TOTAL DIVIDENDS PAID (M USD)

NET CHANGE IN CASH FLOW (M USD)

FREE CASH FLOW (M USD)

SHARE-BASED COMPENSATION (M USD)

1993	1994	1995	1996	1997	1998	1999			2000	2001	2002	2003	2004			2005	2006	2007	2008	2009		2010			2011	2012	2013	2014	2015			2016	2017	2018	2019	2020	2021	2022	2022	2023	2024
0	1	1	1	2	1	1	1	1	2	-1	0	0	0	0	0	1	-5	-22	-7	2	-7	3	2	3	2	1	2	10	0	10	0	-11	-12	-12	-8	-6	-5	-5	-7	-9	-8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
0	-1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	-8	0	0	0	8	0	0	0	0	0	0	0	0	0
0	0	0	-2	-2	-4	1	-4	1	-3	-3	1	4	0	4	0	0	0	-1	-3	0	-3	-1	0	-1	-1	-2	-3	0	-2	0	-2	0	6	0	-1	1	13	13	-4	0	-1
0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	20	7	3	7	2	2	1	1	0	1	3	1	2	0	3	3	3	3	2	0	0	3	4	3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-1	0	-1	2	-1	2	0	-3	2	5	0	5	0	2	-1	0	0	6	0	3	6	3	3	0	0	4	0	4	0	0	-3	-10	-7	-3	8	8	-9	-6	-7
0	0	0	0	-1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1	0	0	0	0	0	0	0	0	0
0	0	0	-1	-4	-2	0	-2	0	0	-1	1	-4	-2	-4	-2	-1	8	-26	0	0	0	0	0	0	0	3	0	-1	-1	-1	-1	-1	0	0	0	0	-5	-5	0	0	0
0	0	0	-1	-2	-1	1	-1	1	0	-1	2	-3	-1	-3	-1	-1	8	-25	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	-5	-5	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	-3	-1	-3	-2	-1	-2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	3
0	0	0	15	0	0	0	0	0	0	0	0	0	1	0	1	0	1	5	0	0	0	0	0	0	0	-2	1	-3	0	-3	0	15	2	10	0	0	10	10	0	0	0
0	0	0	15	0	0	0	0	0	0	0	0	0	1	0	1	0	1	11	0	-2	0	-3	-2	-3	0	-2	1	-3	-1	-3	-1	15	2	10	0	2	9	9	0	0	2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-3	3	0	3	-1	0	-1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	12	-4	-4	3	-4	3	0	-5	4	1	0	1	0	2	8	-15	0	3	0	0	3	0	2	1	1	0	-3	0	-3	13	-2	0	-8	-1	12	12	-9	-6	-4
-0.36	0.71	0.66	-1.9	-1.93	-2.87	2.27	0	0	-0.72	-4.13	2.24	4.49	0.38	0	0	2.43	-1.91	-1.47	-0.32	6.41	0	3.63	0	0	2.85	-0.83	0.39	3.44	-1.47	0	0	-1.2	-4.15	-10.47	-8.04	-3.34	8.01	8	-9.81	-6.85	-7.3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

API Docs Get API Key

IRIDEX Stock Quarterly Figures

REVENUE (M USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (M USD)

NET INCOME (M USD)

NET INCOME GROWTH (%)

SHARES (M)

1994 Q1	1994 Q2	1994 Q3	1994 Q4	1995 Q1	1995 Q2	1995 Q3	1995 Q4	1996 Q1	1996 Q2	1996 Q3	1996 Q4	1997 Q1	1997 Q2	1997 Q3	1997 Q4	1998 Q1	1998 Q2	1998 Q3	1998 Q4	1999 Q1	1999 Q2	1999 Q3	1999 Q4	2000 Q1	2000 Q2	2000 Q3	2000 Q4	2001 Q1	2001 Q2	2001 Q3	2001 Q4	2002 Q1	2002 Q2	2002 Q3	2002 Q4	2003 Q1	2003 Q2	2003 Q3	2003 Q4	2004 Q1	2004 Q2	2004 Q3	2004 Q4	2005 Q1	2005 Q2	2005 Q3	2005 Q4	2006 Q1	2006 Q2	2006 Q3	2006 Q4	2007 Q1	2007 Q2	2007 Q3	2007 Q4	2008 Q1	2008 Q2	2008 Q3	2008 Q4	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2010 Q1	2010 Q2	2010 Q3	2010 Q4	2011 Q1	2011 Q2	2011 Q3	2011 Q4	2012 Q1	2012 Q2	2012 Q3	2012 Q4	2013 Q1	2013 Q2	2013 Q3	2013 Q4	2014 Q1	2014 Q2	2014 Q3	2014 Q4	2015 Q1	2015 Q2	2015 Q3	2015 Q4	2016 Q1	2016 Q2	2016 Q3	2016 Q4	2017 Q1	2017 Q2	2017 Q3	2017 Q4	2018 Q1	2018 Q2	2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4e
1	1	1	2	2	2	2	2	2	2	2	4	3	4	4	5	5	6	5	6	5	6	6	8	8	8	8	7	5	7	6	7	6	7	6	9	7	7	8	8	7	8	8	9	8	9	9	10	8	8	9	9	12	15	13	14	11	12	11	12	10	10	10	11	10	9	2	9	8	8	8	8	8	8	7	9	8	9	9	10	10	10	10	11	10	9	9	12	11	11	9	12	10	10	10	10	9	10	11	11	10	10	10	11	9	6	8	12	11	13	13	15	13	13	14	15	13	12	12	12	11	12	11	12	11	13	12	14
–	–	–	100.00	–	–	–	–	–	–	–	100.00	-25.00	33.33	–	25.00	–	20.00	-16.67	20.00	-16.67	20.00	–	33.33	–	–	–	-12.50	-28.57	40.00	-14.29	16.67	-14.29	16.67	-14.29	50.00	-22.22	–	14.29	–	-12.50	14.29	–	12.50	-11.11	12.50	–	11.11	-20.00	–	12.50	–	33.33	25.00	-13.33	7.69	-21.43	9.09	-8.33	9.09	-16.67	–	–	10.00	-9.09	-10.00	-77.78	350.00	-11.11	–	–	–	–	–	-12.50	28.57	-11.11	12.50	–	11.11	–	–	–	10.00	-9.09	-10.00	–	33.33	-8.33	–	-18.18	33.33	-16.67	–	–	–	-10.00	11.11	10.00	–	-9.09	–	–	10.00	-18.18	-33.33	33.33	50.00	-8.33	18.18	–	15.38	-13.33	–	7.69	7.14	-13.33	-7.69	–	–	-8.33	9.09	-8.33	9.09	-8.33	18.18	-7.69	16.67
100.00	100.00	100.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	33.33	50.00	50.00	60.00	60.00	50.00	40.00	50.00	60.00	50.00	50.00	50.00	50.00	62.50	50.00	57.14	40.00	42.86	50.00	42.86	50.00	42.86	50.00	44.44	42.86	42.86	37.50	50.00	42.86	37.50	37.50	44.44	37.50	44.44	44.44	50.00	50.00	50.00	44.44	55.56	41.67	40.00	46.15	42.86	36.36	41.67	36.36	33.33	50.00	40.00	50.00	45.45	50.00	44.44	50.00	44.44	50.00	37.50	37.50	50.00	37.50	50.00	42.86	44.44	50.00	44.44	44.44	50.00	50.00	50.00	50.00	45.45	50.00	44.44	44.44	41.67	45.45	45.45	44.44	41.67	40.00	40.00	40.00	20.00	33.33	40.00	36.36	36.36	40.00	40.00	40.00	36.36	33.33	33.33	37.50	41.67	36.36	46.15	38.46	40.00	38.46	46.15	42.86	40.00	38.46	41.67	41.67	33.33	36.36	41.67	36.36	41.67	45.45	30.77	33.33	28.57
1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	3	3	3	2	3	3	3	3	4	4	5	4	4	2	3	3	3	3	3	3	4	3	3	3	4	3	3	3	4	3	4	4	5	4	4	4	5	5	6	6	6	4	5	4	4	5	4	5	5	5	4	1	4	4	3	3	4	3	4	3	4	4	4	4	5	5	5	5	5	5	4	4	5	5	5	4	5	4	4	4	2	3	4	4	4	4	4	4	4	3	2	3	5	4	6	5	6	5	6	6	6	5	5	5	4	4	5	4	5	5	4	4	4
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1	-3	-4	0	-1	-15	0	0	0	-6	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	8	0	0	0	0	0	0	0	-10	-1	-2	-3	-5	-3	-3	-3	-2	-3	-2	-1	-1	-1	-2	-1	0	-2	1	-2	-2	-2	-2	-1	-1	-2	-2	-1	-2	-3	-2	-1	0	-1	0	-1	0
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	200.00	33.33	–	–	1,400.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-90.00	100.00	50.00	66.67	-40.00	–	–	-33.33	50.00	-33.33	-50.00	–	–	100.00	-50.00	–	–	-150.00	-300.00	–	–	–	-50.00	–	100.00	–	-50.00	100.00	50.00	-33.33	-50.00	–	–	–	–	–
4.52	4.51	4.51	4.52	4.53	4.55	4.56	4.7	5.7	6.76	6.75	6.71	6.64	6.67	6.85	6.86	6.81	6.86	6.7	6.69	6.77	6.74	6.74	6.83	7.1	7.36	7.28	7.12	6.71	6.87	6.89	6.99	6.84	6.86	6.94	6.99	6.91	6.92	7.04	7.34	7.08	7.79	7.24	7.53	7.32	7.96	8.1	8.14	7.59	7.69	7.76	7.81	8.08	8.2	8.22	8.68	8.82	8.82	8.82	8.82	9.83	10.11	8.9	8.93	9.99	10.2	10.26	10.2	10.22	10.23	10.25	10.2	8.93	10.29	9.01	8.82	9.8	10.01	10	9.89	10.53	10.41	10.26	10.24	10.11	10.03	10.09	10.09	10.14	10.09	10.13	10.44	11.52	11.55	11.57	11.59	11.63	11.64	11.93	13.6	13.63	13.65	13.77	13.78	13.79	13.79	13.89	13.9	14.35	16.31	15.82	15.87	15.88	15.89	15.99	15.99	16	16.04	16.23	16.25	16.25	16.29	16.58	16.63	16.73	16.79	17.01	17.01

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Gross Margin

EBIT and EBIT Margin

Net Income and Earnings Per Share (EPS)

Shares Outstanding

Analyst Estimates

API Docs Get API Key

IRIDEX stock margins

The IRIDEX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IRIDEX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IRIDEX.

3 Years
5 Years
10 Years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

API Docs Get API Key

IRIDEX Stock Sales Revenue, EBIT, Earnings per Share

The IRIDEX earnings per share therefore indicates how much revenue IRIDEX has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Sales per Share

EBIT per share

Earnings per Share

Details

API Docs Get API Key

IRIDEX business model

IRIDEX Corp is a global medical technology company that specializes in the development, manufacturing, marketing, and distribution of innovative laser-based medical devices and services. The company was originally founded in 1989 and is headquartered in Mountain View, California. IRIDEX's business model is divided into various divisions, each serving different markets. The divisions include ophthalmology, otolaryngology (ENT), gynecology and urology, as well as scientific research. The company offers a wide range of high-tech laser systems that can be used to treat various conditions, such as retinal diseases, glaucoma, nasal and throat disorders, gynecological and urological conditions, and other medical applications. One of the most well-known divisions of IRIDEX is ophthalmology, which offers a wide range of laser systems for the treatment of retinal diseases. These retinal diseases include diabetic retinopathy, retinal edema, age-related macular degeneration, and retinal detachment. The company also has a high-tech system called Cyclo G6TM, which is used for the treatment of glaucoma. This system can also be used in conjunction with other devices, such as ultrasound systems, for optimized clinical effectiveness. The ENT division offers laser systems for the treatment of nasal and throat disorders, such as snoring, polyps, stenosis, and tumors. The range of laser systems varies from simple systems to advanced systems that can be connected to a flexible endoscope for more precise treatment. IRIDEX's gynecology and urology division offers laser systems for various applications, such as urinary incontinence, bladder problems, tumor removal, prostate tissue removal, and medical treatments to improve sexual function. Laser systems can also be used in combination with other medical devices, such as ultrasound systems. The company places great emphasis on scientific research and development to create and introduce innovative technologies to the market. Therefore, IRIDEX collaborates closely with various research institutes, universities, and medical professionals to further develop its technological advances. The company is also committed to providing comprehensive training and support to its customers to ensure that they use the devices safely and effectively. Overall, IRIDEX Corp has established itself as an innovative and powerful multinational company in the field of medical technology. The company is constantly striving to expand its range of products and services and impress its customers with its high-quality solutions. IRIDEX is confident that it will continue to play a significant role in the medical technology industry in the future.

API Docs Get API Key

IRIDEX SWOT Analysis

Strengths

IRIDEX Corp is a leading global provider of innovative laser-based medical solutions. Their cutting-edge technology and expertise in ophthalmology have positioned them as a trusted brand in the industry.

The company's strong intellectual property portfolio gives them a competitive advantage and protects their innovations from being easily replicated by competitors.

IRIDEX Corp has established a strong distribution network worldwide, enabling them to reach a wide customer base and expand their market presence.

Weaknesses

The company heavily relies on a limited number of key customers for a significant portion of their revenue, making them vulnerable to changes in customer demand and potential loss of key accounts.

IRIDEX Corp faces intense competition from well-established players in the medical device industry. Their ability to differentiate themselves and maintain market share can be challenging.

As a technology-driven company, IRIDEX Corp is exposed to the risk of rapid technological advancements that could render their current products obsolete or less competitive.

Opportunities

The global demand for minimally invasive medical treatments is growing, presenting an opportunity for IRIDEX Corp to expand their market and offer their advanced laser-based solutions to a broader range of medical specialties.

Advancements in healthcare infrastructure and access to medical services in emerging markets provide IRIDEX Corp with an opportunity to tap into new geographical regions and increase their customer base.

The increasing prevalence of ocular diseases, such as glaucoma and diabetic retinopathy, presents a significant market opportunity for IRIDEX Corp to address unmet medical needs and develop targeted treatments.

Threats

IRIDEX Corp operates in a highly regulated industry, subject to rigorous compliance requirements. Any failure to comply with regulations and standards could result in legal and financial consequences.

The ongoing COVID-19 pandemic poses a threat to the company's operations, as it has disrupted global healthcare systems and caused delays in elective surgeries, leading to a potential decrease in demand for their products.

Intense competition and the potential entry of new players in the market pose a threat to IRIDEX Corp's market share and profitability.

API Docs Get API Key

IRIDEX Segments

IRIDEX Revenue by Segment (1/2)

3 Years
5 Years
Max

Retina

Recurring revenues

Systems

Cyclo G6

Other

Product and Service, Other

Details

IRIDEX Revenue by Segment (2/2)

3 Years
5 Years
Max

Service Contract Revenues

Service

Details

IRIDEX Revenue by Region

3 Years
5 Years
10 Years
Max

United States

Europe

Asia Pacific

Europe, Middle East and Africa

Asia/Pacific Rim

Asia pacific rim

Rest of Americas

Americas, excluding the U.S

Details

API Docs Get API Key

IRIDEX Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

API Docs Get API Key

IRIDEX historical P/E ratio, EBIT multiple, and P/S ratio

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides IRIDEX's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates IRIDEX's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots IRIDEX's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if IRIDEX grows earnings faster than its peers.

API Docs Get API Key

IRIDEX annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

API Docs Get API Key

IRIDEX shares outstanding

The number of shares was IRIDEX in 2025 — This indicates how many shares 16.439 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 Years
5 Years
10 Years
25 Years
Max

Number of stocks

Details

API Docs Get API Key

Unfortunately, there are currently no price targets and forecasts available for IRIDEX.

API Docs Get API Key

IRIDEX Earnings Estimates

Date	EPS estimate	Revenue Estimate	Quarterly report
3/26/2026	-0.02USD	15.03 MUSD	2025 Q4
3/5/2026	-0.02USD	0USD	2025 Q4
8/12/2025	-0.09USD	13.46 MUSD	2025 Q2
11/12/2024	-0.09USD	12.75 MUSD	2024 Q3
5/9/2024	-0.08USD	13.46 MUSD	2024 Q1
3/7/2024	-0.09USD	14.64 MUSD	2023 Q4
11/8/2023	-0.11USD	15.94 MUSD	2023 Q3
8/14/2023	-0.12USD	15.12 MUSD	2023 Q2
5/10/2023	-0.12USD	14.72 MUSD	2023 Q1
3/8/2023	-0.1USD	15.79 MUSD	2022 Q4
11/10/2022	-0.15USD	14.08 MUSD	2022 Q3
8/15/2022	-0.16USD	14.13 MUSD	2022 Q2
5/12/2022	-0.16USD	13.62 MUSD	2022 Q1
3/10/2022	-0.11USD	14.91 MUSD	2021 Q4
11/11/2021	-0.15USD	12.08 MUSD	2021 Q3
8/12/2021	-0.16USD	11.78 MUSD	2021 Q2
5/11/2021	-0.14USD	10.05 MUSD	2021 Q1
3/22/2021	-0.11USD	12.44 MUSD	2020 Q4
11/9/2020	-0.18USD	7.9 MUSD	2020 Q3
8/6/2020	-0.23USD	6.03 MUSD	2020 Q2
5/11/2020	-0.17USD	9.65 MUSD	2020 Q1
3/12/2020	-0.16USD	11.04 MUSD	2019 Q4
11/7/2019	-0.18USD	10.23 MUSD	2019 Q3
8/6/2019	-0.22USD	11.1 MUSD	2019 Q2
5/2/2019	-0.24USD	10.61 MUSD	2019 Q1
3/5/2019	-0.25USD	11.01 MUSD	2018 Q4
11/1/2018	-0.29USD	9.79 MUSD	2018 Q3
8/2/2018	-0.33USD	9.34 MUSD	2018 Q2
5/3/2018	-0.34USD	8.93 MUSD	2018 Q1
3/8/2018	-0.28USD	10.37 MUSD	2017 Q4
11/2/2017	-0.15USD	10.83 MUSD	2017 Q3
8/3/2017	-0.12USD	11.48 MUSD	2017 Q2
5/3/2017	-0.12USD	11.69 MUSD	2017 Q1
3/8/2017	0USD	12.71 MUSD	2016 Q4
11/3/2016	-0.03USD	11.37 MUSD	2016 Q3
8/4/2016	0.01USD	12.08 MUSD	2016 Q2
5/5/2016	0.04USD	12.06 MUSD	2016 Q1
3/3/2016	0.04USD	12.18 MUSD	2015 Q4
11/4/2008	-0.04USD	12.71 MUSD	2008 Q3
8/12/2008	-0.04USD	13.09 MUSD	2008 Q2
5/13/2008	-0.01USD	13.27 MUSD	2008 Q1
4/10/2008	-0.05USD	15.51 MUSD	2007 Q4
11/19/2007	-0.17USD	15.63 MUSD	2007 Q3
8/14/2007	-0.12USD	15.52 MUSD	2007 Q2
7/9/2007	0.01USD	15.74 MUSD	2007 Q1
4/3/2007	0.04USD	9.15 MUSD	2006 Q4
12/26/2006	0.07USD	10.83 MUSD	2006 Q3
8/3/2006	0.05USD	10.25 MUSD	2006 Q2
5/15/2006	0.02USD	9.19 MUSD	2006 Q1
2/16/2006	0.07USD	10.45 MUSD	2005 Q4
10/25/2005	0.05USD	9.29 MUSD	2005 Q3
8/3/2005	0.03USD	8.95 MUSD	2005 Q2
4/29/2005	-0.01USD	8.17 MUSD	2005 Q1
2/15/2005	0.06USD	9.29 MUSD	2004 Q4
10/19/2004	0.03USD	8.4 MUSD	2004 Q3
7/27/2004	0.04USD	7.82 MUSD	2004 Q2
5/4/2004	0.04USD	7.92 MUSD	2004 Q1

IRIDEX shareholders

%	Name	Stocks	Change	Date
9.41316%	Topcon Corp	1,618,122	+6,000	4/1/2025
6.23743%	Stanley Manne Trust	1,072,215		4/1/2025
5.81734%	Paragon JV Partners, LLC	1,000,000		6/30/2025
3.40787%	The Vanguard Group, Inc.	585,813	-8,974	6/30/2025
2.68593%	Roland (Brent Alexander)	461,711	+461,711	4/1/2025
2.20337%	Renaissance Technologies LLC	378,760	-400	6/30/2025
1.74520%	Moore (William M)	300,000	+12,024	8/18/2025
1.30127%	Roland Family Support Trust	223,688	+223,688	4/1/2025
1.07173%	AMH Equity, Ltd.	184,230	-5,770	9/30/2025
1.05642%	Roland (Glenn Cuthbert)	181,599	+181,599	4/1/2025
0.93137%	Grove (Robert Earle)	160,103	+39,267	4/1/2025
0.76653%	Geode Capital Management, L.L.C.	131,767	-1,338	6/30/2025
0.75348%	Meridian OHC Partners, L.P.	129,523	+60,724	4/24/2025
0.73578%	Bruce (David I)	126,480	+53,243	4/1/2025
0.59169%	Ludlum (Kenneth E.)	101,711	+39,267	4/1/2025
0.58257%	Mercer (Patrick)	100,143	-23,850	10/1/2025
0.53891%	Huss (Beverly A)	92,639	+65,167	4/23/2025
0.52348%	BouHabib (Bassem)	89,987	+89,987	4/1/2025
0.39876%	Dizon (Romeo R)	68,547	+9,575	9/12/2025
0.38217%	Apexium Financial, LP	65,695		6/30/2025
0.32999%	Thompson, Davis & Co., Inc. (Asset Management)	56,726	+56,726	6/30/2025
0.26014%	State Street Investment Management (US)	44,718		6/30/2025
0.24026%	Perkins Capital Management, Inc.	41,300	-6,000	9/30/2025
0.22476%	Susquehanna International Group, LLP	38,636	+38,636	6/30/2025
0.18133%	Citadel Advisors LLC	31,171	-43,077	6/30/2025
0.17516%	Newton Investment Management North America, LLC	30,110		6/30/2025
0.14666%	XTX Markets LLC	25,211	+14,900	6/30/2025
0.14488%	Northern Trust Investments, Inc.	24,905	-286	6/30/2025
0.11786%	BlackRock Institutional Trust Company, N.A.	20,260	-33,370	6/30/2025
0.08726%	Roland (Leigh Ann)	15,000	+15,000	4/1/2025
0.05817%	Hightower Advisors, LLC	10,000		6/30/2025
0.03179%	Tower Research Capital LLC	5,464	-497	6/30/2025
0.00832%	BNY Mellon Asset Management	1,430		6/30/2025
0.00640%	Group One Trading, L.P.	1,100		6/30/2025
0.00407%	Raymond James Financial Services Advisors, Inc.	700	+700	6/30/2025
0.00072%	BofA Global Research (US)	123	+15	6/30/2025
%	Innealta Capital, LLC		-17	9/30/2024
%	Wolverine Trading, LLC		-16,279	6/30/2024
%	Osaic Holdings, Inc.		-1,000	12/31/2024
%	Venturi Private Wealth		-750	3/31/2025
%	Simplex Trading, LLC		-125	6/30/2025
%	Long Focus Capital Management LLC		-38,173	3/31/2025
%	Dimensional Fund Advisors, Ltd.		-7,315	4/30/2025
%	Morgan Stanley Smith Barney LLC		-1,000	12/31/2024
%	Northern Trust Global Investments		-2,000	3/31/2025
%	RBC Capital Partners		-273	9/30/2024
%	Truist Bank		-12,979	3/31/2025
%	Bridgeway Capital Management, LLC		-70,000	3/31/2025
%	Wells Fargo Bank, N.A.		-98	6/30/2024
%	ARS Investment Partners LLC		-110,060	6/30/2025
%	BlackRock Investment Management, LLC		-3,038	6/30/2025
%	Manulife Investment Management (North America) Limited		-360	4/30/2025
%	Dimensional Fund Advisors, L.P.		-14,549	6/30/2025
%	J.P. Morgan Securities LLC		-27	6/30/2025
%	UBS Financial Services, Inc.		-1,502	6/30/2025
%	Concurrent Investment Advisors, LLC		-21,944	6/30/2025
%	West Paces Advisors Inc.		-135	6/30/2025

API Docs Get API Key

IRIDEX Executives and Management Board

Mr. Patrick Mercer

(53)

President, Chief Executive Officer, Chief Operating Officer, Director · since 2018

Compensation1.11 MUSD

Compensation1.11 M USD

Mr. William Moore

(76)

Independent Director · since 2007

864,466USD

Compensation864,466 USD

Mr. Bassem Bouhabib

(49)

Vice President - International Sales

529,307USD

Compensation529,307 USD

Mr. Romeo Dizon

(67)

Chief Financial Officer · since 2025

122,573USD

Compensation122,573 USD

Mr. Scott Shuda

(59)

Independent Chairman of the Board

84,756USD

Compensation84,756 USD

API Docs Get API Key

IRIDEX Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite

3 companies

#	Name	1M	3M	6M	1Y	2Y
1	Alcon Supplier	-0,27	0,45	0,64	0,25	0,67
2	Canon	-0,89	-0,66	-0,71	-0,70	0,58
3	Menicon	0,72	0,81	0,79	0,89	0,55

API Docs Get API Key

Most common questions regarding IRIDEX

The business model of IRIDEX Corp focuses on developing, manufacturing, and marketing medical laser systems and delivery devices for the treatment of eye diseases and conditions. With a comprehensive portfolio of products, the company aims to provide innovative solutions to both ophthalmologists and patients. By leveraging its cutting-edge laser technology, IRIDEX Corp aims to improve the standards of care and enhance patient outcomes in the field of ophthalmology.

IRIDEX Corporation is a leading company specializing in the development, manufacture, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company specializes in two main divisions: ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "PASCAL Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. IRIDEX's ophthalmology division also offers other innovative products such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, offering products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin issues like acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessories, including consumables, as well as services such as training and support. IRIDEX sells its products in over 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer care, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessories for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as the leading product line for global ophthalmology and aesthetic dermatology. IRIDEX Corporation is a leading company specialized in the development, manufacturing, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers, including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company is specialized in two main divisions: Ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "Pascal Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. The IRIDEX ophthalmology division also offers other innovative products, such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, where it offers products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin problems such as acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessory products, including consumables, and services such as training and support. IRIDEX sells its products in more than 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer support, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessory products for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as a leading product line for global ophthalmology and aesthetic dermatology.

API Docs Get API Key

Fair ValuePRO

1.16 USD

Over-/UndervaluationPRO

8.0% undervalued

Sector

Health

Industry

Health Care Equipment

Number of shares

17,190,000

Employees

Revenue per Employee

517,755.32 USD

Revenue growth Ø5 years

6.01 %

EBIT growth Ø5 years

4.76 %

Net Income growth Ø5 years

7.08 %

Website iridex.com

Country

United States 🇺🇸

Currency

USD

Initial public offering

Feb 16, 1996

ISIN

US4626841013

Cusip

462684101

Sedol

2476375

Market capitalization

23.72 M USDMicro Cap

52-Week Range

1.21–1.54USD

IRIDEX Directors Dealings

Quality Investing

Details

0 / 10

Sales growth (10Y) > 5%

Revenue growth (3Y) > 5 %

EBIT growth (10Y) > 5%

EBIT growth (3Y) > 5 %

Net debt < 4x EBIT

Profitable since 10Y+

EBIT Drawdown (10Y) < 50%

Return on Equity (ROE) > 15%

ROCE > 15%

Return Expectation > 10%

PEG

—

P/E ratio

-2.48

P/Ee 2025

-4.67

P/Ee 2026

-18.03

P/Ee 2027

25.24

P/Ee 2028

12.62

P/S

0.45

P/Se

0.41

EV/EBIT

—

P/B Ratio

11.31

ROE (Return on Equity)

-424.89 %

ROA (Return on Assets)

-30.58 %

ROCE (Return on Capital Employed)

-395.9 %

ROIC (Return on Invested Capital)

-339.13 %

Gross Margin

40.07 %

EBIT Margin

-17.06 %

Net Margin

-18.31 %

EPS (Earnings Per Share)

-0.54 USD

Net Debt / EBIT

-0.04

Debt/Equity

1.31

Last updated Mar 18, 2026, 4:11 AM

IRIDEX Peer Group

Abbott Laboratories

Intuitive Surgical Inc

Danaher Corp

Stryker Corp

Becton Dickinson and Co

Boston Scientific Corp

IRIDEX Ticker

NASDAQ · IRIX

IRIDEX FIGI

IRIX:US · BBG000BZB346IRIX:UA · BBG000BZB3G3IRIX:UC · BBG000BZB3W5IRIX:UN · BBG000BZB4G1IRIX:UP · BBG000BZB4T7IRIX:UQ · BBG000BZB578IRIX:UB · BBG000BZB5C2IRIX:UM · BBG000BZB5Y8IRIX:UX · BBG000BZB658IRIX:UD · BBG000BZB9Q9IRIX:UF · BBG000BZBCG3IRIX:VY · BBG000BZBCR1IRIX:VJ · BBG000BZBD26IRIX:VK · BBG000BZBDG1IRIX:VF · BBG00DJD7FX5IRIXUSD:EP · BBG00RFD4XQ0IRIXUSD:EZ · BBG00RFD4XS8IRIXUSD:XS · BBG00RFD4XT7IRIXUSD:X2 · BBG00RFD4XV4IRIXUSD:XH · BBG00RFD4XX2IRIXUSD:XF · BBG00RFD4XZ0IRIXUSD:XE · BBG00RFD4Y15IRIXUSD:XJ · BBG00RFD4Y24IRIXUSD:XL · BBG00RFD4Y33IRIXUSD:XG · BBG00RFD4Y42IRIXUSD:XO · BBG00RFD4Y51IRIXUSD:XA · BBG00RFD4Y97IRIXUSD:E1 · BBG00RFD4YB4IRIXUSD:XT · BBG00RFD4YC3IRIXUSD:XW · BBG00RFD4YD2IRIXUSD:XU · BBG00RFD4YF0IRIXUSD:XV · BBG00RFD4YH8IRIXUSD:XM · BBG00RFD4YK4IRIXUSD:XQ · BBG00RFD4YL3IRIXUSD:XX · BBG00RFD4YM2IRIXUSD:XZ · BBG00RFD4YN1IRIXUSD:X1 · BBG00RFD4YQ8IRIXUSD:EU · BBG00RFD4YV2IRIXEUR:EP · BBG00SKXKR01IRIXEUR:EZ · BBG00SKXKR29IRIXEUR:XS · BBG00SKXKR65IRIXEUR:X2 · BBG00SKXKR74IRIXEUR:XH · BBG00SKXKR92IRIXEUR:XF · BBG00SKXKRC8IRIXEUR:XE · BBG00SKXKRF5IRIXEUR:XJ · BBG00SKXKRG4IRIXEUR:XL · BBG00SKXKRH3IRIXEUR:XG · BBG00SKXKRJ1IRIXEUR:XO · BBG00SKXKRL8IRIXEUR:XA · BBG00SKXKRQ3IRIXEUR:E1 · BBG00SKXKRR2IRIXEUR:XT · BBG00SKXKRS1IRIXEUR:XW · BBG00SKXKRT0IRIXEUR:XU · BBG00SKXKRV7IRIXEUR:XV · BBG00SKXKRX5IRIXEUR:XM · BBG00SKXKRY4IRIXEUR:XQ · BBG00SKXKRZ3IRIXEUR:XX · BBG00SKXKS18IRIXEUR:XZ · BBG00SKXKS27IRIXEUR:X1 · BBG00SKXKS54IRIXEUR:EU · BBG00SKXKS90IRIX:VG · BBG00X1LKYS2IRIX:VP · BBG00X1Q07R3

All fundamentals about IRIDEX

Our stock analysis for IRIDEX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRIDEX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

IRIDEX Directors Dealings→

IRIDEX Stocks→

IRIDEX Market capitalization→

IRIDEX Debt→

IRIDEX Liabilities→

IRIDEX Equity→